BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ActivBiotics And Metaphore Pharmaceuticals, Inc. Complete Merger Creating Late-Stage Company Addressing Serious Infections And Inflammation


1/11/2006 12:04:40 PM

LEXINGTON, Mass., Jan. 11 /PRNewswire/ -- ActivBiotics, Inc. and Metaphore Pharmaceuticals, Inc. announced today that stockholder approval of the previously announced merger has been received and the merger is now complete. The merger, first announced in early December 2005, creates a late-stage company with two clinical stage compounds and a robust pipeline of preclinical candidates. In connection with the transaction, ActivBiotics has issued, and Metaphore stockholders have received, shares of ActivBiotics stock and Metaphore will become a wholly owned subsidiary of ActivBiotics.

The ActivBiotics Board has been increased to 11 members, adding significant late stage clinical development and commercial experience. The new ActivBiotics board will now consist of the following members:

Alan W. Dunton, M.D., (Chairman of the Board). Former President and CEO, Metaphore Pharmaceuticals, Inc. Constantine E. Anagnostopoulos, Ph.D., retired officer of Monsanto, former managing partner of Gateway Associates Jerry Benjamin, General Partner, Advent Venture Partners Joshua Boger, Ph.D., President, Chairman and Chief Executive Officer, Vertex Pharmaceuticals, Inc. Gerry Brunk, Venture Partner, MDS Capital Jeff Courtney, General Partner, VenGrowth Capital Partners Richard U. DeSchutter, Former Chairman and CEO of DuPont Pharmaceuticals, senior executive at G.D. Searle, Monsanto, Pharmacia Walter Gilbert, Ph.D., General Partner, BioVentures LLC, Nobel Laureate Steven C. Gilman, Ph.D., President & CEO, ActivBiotics, Inc. Michael Hanson, Founding Partner, Barnard Life Sciences, LLC, and former senior executive with at Eli Lilly and Company. John Littlechild, General Partner, HealthCare Ventures LLC

As previously announced, the ActivBiotics management team, headed by Steven Gilman, Ph.D., President and Chief Executive Officer, will continue to run the combined company out of its headquarters in Lexington, MA.

About ActivBiotics

ActivBiotics, Inc. is a private biopharmaceutical company located in Lexington, MA, focused on the discovery, development and commercialization of breakthrough antibacterials for high-value chronic and infectious disease markets. The Company's lead product candidate, rifalazil, is being studied in a pivotal study in patients with intermittent claudication, a manifestation of lower extremity arterial disease. The Company's lead pre-clinical compound in its pipeline of novel rifamycins, ABI-0043, shows significant potential for the treatment of infections caused by Gram-positive pathogens, including Staphylococcus aureus and MRSA (methicillin-resistant Staphylococcus aureus). For more information, please visit http://www.activbiotics.com.

This press release contains forward-looking statements based on information available to ActivBiotics and Metaphore as of the date hereof. In some cases, you can identify these forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology. Actual results could differ materially from the results stated or implied by such forward- looking statements due to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, general economic and business conditions, changes in governmental laws and regulations relating to the development and commercialization of pharmaceutical products, and competition in the pharmaceutical industry. ActivBiotics and Metaphore disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

ActivBiotics, Inc.

CONTACT: Glenn Kazo, Chief Business Officer of ActivBiotics, Inc.,+1-781-372-4864, gkazo@activbiotics.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES